F. Zannad

发表

2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension.

P. Nilsson, F. Zannad, S. Laurent, 2013, Journal of hypertension.

Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial.

P. Rossignol, A. Latosinska, N. Girerd, 2024, Heart.

High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT.

S. de Denus, Jiankang Liu, B. Claggett, 2024, International journal of cardiology.

MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials

Z. Younossi, C. Parikh, N. Girerd, 2024, Journal of internal medicine.

Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study.

F. Vasques-Nóvoa, João Pedro Ferreira, A. Leite-Moreira, 2024, Atherosclerosis.

Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure

Alexander E. Lopez, Andrew L Blumenfeld, J. Cook, 2020, Nature Communications.

Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Preserved

M. Mattheus, B. Kraus, S. Anker, 2024, European journal of heart failure.

Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long‐term outcomes

J. Lindenfeld, T. Rogers, E. Galle, 2024, European journal of heart failure.

Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy

P. Gouda, J. Januzzi, Justin A. Ezekowitz, 2024, Cardiovascular diabetology.

The Future of Clinical Trials.

B. Pitt, F. Zannad, 2024, Circulation.

Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.

J. Januzzi, Riccardo Perfetti, Justin A. Ezekowitz, 2024, Journal of the American College of Cardiology.

Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program.

J. Prochaska, J. Januzzi, João Pedro Ferreira, 2024, Journal of the American College of Cardiology.

Integrating liver endpoints in clinical trials of cardiovascular and kidney disease.

J. Butler, Veronica Miller, Arun J. Sanyal, 2024, Nature medicine.

Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort

P. Rossignol, E. Bozec, N. Girerd, 2024, European journal of heart failure.

Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis

A. Ofstad, S. Anker, J. Butler, 2024, Diabetes, obesity & metabolism.

Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity

A. Tvarijonaviciute, E. Guillot, Chelsea A. Iennarella-Servantez, 2024, Scientific reports.

Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry.

W. Tay, A. Voors, T. Teng, 2024, European journal of heart failure.

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡

D. Atar, R. de Caterina, J. Camm, 2008, European journal of heart failure.